News-Medical.netEgalet (EGLT) Announces Significant Data from Egalet-001 Category 3 HALStreetInsider.comEgalet (NASDAQ: EGLT) announced positive results from a Category 3 intranasal human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of ...Egalet Announces Positive Top-Line Results from Intranasal Human Abuse ...PR Newswire (press release)Egalet says drug less likely to be abused than other painkillersGlobalPostall 8 news articles »
Egalet (EGLT) Announces Significant Data from Egalet
Rating: 4.5
Diposkan Oleh: Unknown
